Cost-effectiveness analysis of a switch therapy for communityacquired pneumonia
Análisis de costos en una terapia switch en el tratamiento de la neumonía adquirida en comunidad
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Pneumonia is an infectious process resulting from invasion and overgrowth of microorganisms in lung parenchyma, which causes breakdown of defenses and intraalveolar exudates. The term community-acquired pneumonia (CAP) refers to lung infection which appears outside the hospital setting. In the northern hemisphere there are approximately 12 cases of CAP per 1000 inhabitants per year, which account for about one million hospitalizations. The length of the hospital stay is one of the key determinants of institutional costs. The decision to hospitalize should be based on the patient’s stability and clinical condition, as well as the risk of death and complications, the presence or absence of comorbidities, and the psychosocial characteristics. Switch therapy (intravenous to oral) must be initiated early. This study showed that combined treatment with intravenously administrated beta-lactam plus macrolide for three days, switched to an oral macrolide for five days, reduced global costs.
Article visits 240 | PDF visits 55
Downloads
- Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community- acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39:1642–50
- Comité Nacional de Neumonía Adquirida en la Comunidad. Recomendaciones para el diagnostico, tratamiento y prevención de la neumonía adquirida en comunidad en adultos. Rev Colomb Neumol 2003; 15/ supl 3): S1 – S42
- Robledo J, Sierra P, Bedoya F, Londoño A. Porras A. Lujan M. Correa N, et al. Neuominia adquirida en la cominidad en adultos: Un estudio etiológico porspectivo con énfasis en el diagnostico. Rev Colomb Neumol 2003; 15: 7-14.
- Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730–54.
- ATS Borrad Directors. Guideline For Management of Aduls with Community accqyuired Pneumonie. Am J Respir Crit Care Med 2001; 163: 1730-54
- Robledo J, Sierra P, Bedoya F, Londoño A. Porras A. Lujan M. Correa N, Mejia GI, Realte T y Trujillo H. Neuominia adquirida en la cominidad en adultos: Un estudio etiológico porspectivo con énfasis en el diagnostico. Rev Colomb Neumol 2003; 15: 7-14.
- Morales GA, Rodriguez MM, Cepeda O. Contreras RD, Neumonía adquirida en la comunidad. Descripción del perfil de 81 casos hospitalizados durante un periodo de 19 meses en un hospital general de Bogotá. Rev Colomb Neumol 1997; 9 (A): 228.
- Chaparro C, Ortega H, Torres CA, Giraldo H. Neumonía adquirida en la comunidad. Rev Colomb Neumol 1989; 1: 19-24
- Giraldo H, Dueñas R. Neumonias en la clínica Shaio de Bogotá. Rev Colomb Neumol 1997; 1993 5: 171.
- Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11.
- Mundy LM, Oldach D, Awaerter PG et al. Implications for macrolyde treatment in community acquiredpneumonia. The Hopkins CAP Team. Chest 1998; 113: 1201 -6.
- Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 630-1.
- IDSA/ATS Guidelines for CAP in Adults • CID 2007:44 (Suppl 2) S27.
- Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community- acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160:1399-408.
- Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18:777-90.
- Quenzer RW, Pettit KG, Arnold RJ, Kaniecki DJ. Pharmacoeconomic analisis of selected antibiotics in lower respiratory tract infection. Am J manag Care 1997; 3: 1027- 36.
- BMJ, doi:10.1136/bmj.38993.560984.BE (published 7 November 2006).
- Skerrett S. (1999). Diagnostic testing for community acquired pneumonia. Clin Chest Med 20:531-48.
- Guidelines for the management of adults with community-acquired pneumonia. American Thoracic Society, Am J Respir Crit Care Med Vol 163. pp 1730-1754, March 9, 2001.
- Rubin B, Henke M: Inmunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004; 125: 70-8. Saiman L: The use of macrolide antibiotic in patients with FQ. Curr Opin Pulm Med 2004; 10: 515-23.
- Labro Mt. Anti-inflamatory activity of macrolides: a new therapeutic potencial? J Antimicrob Chemother 1998; 41 (suppke): 37-46.
- Kawasaki S, Takizawa H, Takayuky o, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998; 42: 1499-1502
- Tamaoki J, Takeyama K, Yamawaki I, et al. Lipopolysaccharide induced goblet cellhypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 1997; 272: L15 – L 19
- Ichiyama T, Nishikawa M, Yoshitomi T, et al. Clarithromycin inhibits NF – kB activation inhuman peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemotherapy 2001; 45: 44-47.
- Tamaoki J, Kondo M, Kohri K, et al Macrolide antibiotics Project against inmune complex induced lung injury in rats: role of nitric oxide from alveolar macrophages. J immunol 1999; 163: 2909-2915
- Bragonzi A, Worlitzsch D, Pier GB, et al: Nonmucoid Pseudomonas aeruginosa Expresses Alginate in the Lungs of Patients with Cystic Fibrosis and in a Mouse Model. J Infect Dis 2005; 192: 410-9
- Tagaya E, Tamaoki J, Kondo M, et al. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002; 122: 213- 218.
- Banerjee D, Hussain S, Khair O, et al. The effects of oral claritromycin on airway inflammation in moderate to severe chronic obstructive pulmonary disease (COPD) : a double blind randomizes controlled estudy . Eur Respir J 2001; 18: 338s.
- Nixon LS, Boorman J, Papagiannis AJ, et al. The effect of the length of antibiotic treatment on inflammatory markers in chronic obstructive pulmonary disease abstract. www.abstracts-on line.com/abstracts/ATSALL. Accesed January 12 2004.
- Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E, Nikolaizik W: DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 2005; 39: 1-4
- Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronquiolitis treated with low-dose erytromycin. Am j Respir Crit Care Med 1998; 157: 1829 – 19832.
- Khalid M, Al Saghir A, Saleemi S, et al. Azithromycin in bronchiolitis obliteras complicating bone marro transplantation: a preliminary study. Eur Respir J 2005; 25: 490-3.
- Saiman L. The use of macrolide antibiotic in patients with FQ. Curr Opin Pulm Med 2004; 10: 515-23
Information
Journal history
Keywords
QR code
Funding
Directories and indexes
